Arcus Biosciences Inc (RCUS) COM USD0.0001
$0.79
(1.76%)
- Add to watchlist
- This stock can be held in a
$0.79
(1.76%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.79
(1.76%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapies. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. It is focused on creating, developing and commercializing differentiated combination cancer therapies. The Company has five products in clinical development: Domvanalimab, Etrumadenant, Quemliclustat, AB308 and Zimberelimab. Domvanalimab is designed for immune activation and tumour clearance in combination with other immunotherapy and anti-cancer agents. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumour-infiltrating lymphocytes and myeloid cells. Quemliclustat is designed to provide differential benefits relative to monoclonal antibodies. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody.
Contact details
Important dates
General stock information
- Short code:
- RCUS
- ISIN:
- US03969F1093
- Market cap:
- $3.03 billion
- Shares in issue:
- 70.25 million
- Sector:
- Biotechnology
- Exchange:
- New York Stock Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.